|
Market Closed -
NSE India S.E.
10:05:06 16/10/26 pm AEDT
|
5-day change | 1st Jan Change | ||
| 5,050.00 INR | -1.38% |
|
-4.34% | -8.29% |
| 12/10 | Alkem Laboratories Limited Announces Management Appointments, Effective October 12, 2026 | CI |
| 24/09 | Alkem Laboratories Limited Announces Resignation of Nitin Agrawal as Chief Financial Officer | CI |
Company Valuation: Alkem Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 432,909 | 406,055 | 590,890 | 583,680 | 633,575 | 603,803 | - | - |
| Change | - | -6.2% | 45.52% | -1.22% | 8.55% | -4.7% | - | - |
| Enterprise Value (EV) 1 | 433,805 | 393,853 | 587,236 | 578,678 | 632,481 | 590,679 | 575,618 | 566,422 |
| Change | - | -9.21% | 49.1% | -1.46% | 9.3% | -6.61% | -2.55% | -1.6% |
| P/E | 26.3x | 41.3x | 32.9x | 27x | 27.5x | 26.3x | 22.9x | 19.7x |
| PBR | 5.01x | 4.49x | 5.73x | 4.87x | 4.58x | 3.93x | 3.45x | 3.04x |
| PEG | - | -1x | 0.4x | 1.3x | 4.37x | -93.82x | 1.5x | 1.2x |
| Capitalization / Revenue | 4.07x | 3.5x | 4.66x | 4.5x | 4.31x | 3.62x | 3.25x | 2.95x |
| EV / Revenue | 4.08x | 3.4x | 4.64x | 4.46x | 4.3x | 3.54x | 3.09x | 2.77x |
| EV / EBITDA | 21.1x | 24.5x | 26.2x | 23x | 21x | 17.3x | 14.6x | 12.7x |
| EV / EBIT | 24.8x | 30.3x | 30.2x | 26.9x | 24.1x | 19.9x | 16.9x | 14.5x |
| EV / FCF | 55.4x | 27.1x | 33.3x | 45.3x | 42.8x | 57.3x | 28.2x | 22.2x |
| FCF Yield | 1.81% | 3.69% | 3% | 2.21% | 2.33% | 1.75% | 3.55% | 4.51% |
| Dividend per Share 2 | 34 | 25 | 40 | 45 | 53 | 50.29 | 55.4 | 63.85 |
| Rate of return | 0.94% | 0.74% | 0.81% | 0.92% | 1% | 1% | 1.1% | 1.26% |
| EPS 2 | 137.6 | 82.31 | 150.2 | 181.1 | 192.5 | 192 | 221 | 256.1 |
| Distribution rate | 24.7% | 30.4% | 26.6% | 24.8% | 27.5% | 26.2% | 25.1% | 24.9% |
| Net sales 1 | 106,342 | 115,993 | 126,676 | 129,645 | 147,123 | 166,949 | 186,008 | 204,727 |
| EBITDA 1 | 20,529 | 16,094 | 22,455 | 25,122 | 30,052 | 34,204 | 39,337 | 44,427 |
| EBIT 1 | 17,490 | 12,990 | 19,462 | 21,550 | 26,232 | 29,661 | 34,151 | 39,180 |
| Net income 1 | 16,456 | 9,842 | 17,958 | 21,655 | 23,018 | 23,147 | 27,276 | 31,030 |
| Net Debt 1 | 896.1 | -12,202 | -3,654 | -5,003 | -1,094 | -13,125 | -28,185 | -37,381 |
| Reference price 2 | 3,620.70 | 3,396.10 | 4,942.00 | 4,881.70 | 5,299.00 | 5,050.00 | 5,050.00 | 5,050.00 |
| Nbr of stocks (in thousands) | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | 119,565 | - | - |
| Announcement Date | 13/5/22 | 19/5/23 | 29/5/24 | 29/5/25 | 28/5/26 | - | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 26.31x | 3.54x | 17.27x | 1% | 6.36B | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 28.78x | 6.61x | 18.28x | 2.04% | 394.73B | |
| Weighted average by Cap. | 34.71x | 8.19x | 20.03x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALKEM Stock
- Valuation Alkem Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
